This is a bilingual snapshot page saved by the user at 2025-1-17 13:17 for https://app.immersivetranslate.com/word/, provided with bilingual support by Immersive Translate. Learn how to save?

总结报告 专题代号:2415AS1


Research topic title: In vitro antimicrobial activity testing of novel antimicrobial peptides


Summary report


Project Leader (Signed): Wang Ting Date: 202411.12


Trial start and end dates: 202 4.09.18 to 202410.18

总结报告 专题代号:2415AS1


Table of Contents


Abbreviation 2


1. Research topic name and code 3


2 Purpose of the study 3


3 for the test and reference 3


4In vitro antimicrobial test4


4.1 Test strains and their cultivation methods4


4.2 In vitro antimicrobial test method 5


4.3Quality control7


5Reagents & Instruments 8


5.1 Main reagents and culture medium8


5.2 Main Instruments 8


6 test results 9


6.1 Analysis of the in vitro antimicrobial activity of the antimicrobial polypeptide iCAMP016 and the control drug on 48 strains of clinically isolated bacteria9


6.2 In vitro antimicrobial activity analysis of antimicrobial polypeptide iCAMP016 and control drug against 48 strains of yeast fungi19


7 Conclusion of the experiment 28

20 45

总结报告 专题代号:2415AS1


Abbreviations


abbreviation


English

ATCC

American Type Culture Collection

BMD

Broth Microdilution

CICC

China Center of Industrial Culture Collection

CAMHB

Cation Adjusted Mueller-Hinton Broth

CFU

Colony Forming Unit

CLSI

Clinical and Laboratory Standards Institute

DMSO

Dimethyl Sulfoxide

EUCAST

European Committee on Antimicrobial Susceptibility Testing

I

Intermediate

LRSA

Linezolid – resistant Staphylococcus aureus

MHA

Mueller-Hinton Agar

MSSA

Methicillin-sensitive Staphylococcus aureus

MRSA

Methicillin- resistant Staphylococcus aureus

MIC

Minimal Inhibitory Concentration

MOPS

Molar (3-(N-morpholino)-propanesulphonic acid

R

Resistant

RPMI

Rosewell Park MemorialInstitute

S

Susceptible

SDA

Sabouraud Dextrose Agar


Page 20 of 45

总结报告 专题代号:2415AS1


The name of the research topic


Feature Title: In vitro testing of novel antimicrobial peptides


Objectives:


To evaluate the in vitro antimicrobial activity of the novel antimicrobial peptide iCAMP016 against clinically isolated pathogenic bacteria (48 strains) and fungi (48 strains) in China in the past three years. The in vitro antimicrobial activity of marketed antibiotics was compared to provide a reference for the feasibility of the development and marketing of this product.


Test and reference substances


The information of the test sample and the positive control substance is detailed in Table 1.


Table 1 Information on test samples and positive controls


Sample type


The name of the sample


Sample size


content


lot number


Units provided


Test article

iCAMP016


About 53 mg

>99%

20240520


Principal


Positive control


(Bacterial and fungal tests).

BF-30


About 52 mg

20240520

iCAMP018


About 51 mg

20240520

PL-18


About 50 mg

20240520


Positive control


(Bacteriological test)


Clindamycin

100 mg

87.2%

130422-201807


Produced by China Institute for Food and Drug Control


Levofloxacin

100 mg

97.1%

130455-202108


Cefuroxime sodium

1000 mg

≥98%

F0214D


Produced by Dalian Meilun Biotechnology Co., Ltd


Moxifloxacin hydrochloride

200 mg

≥99%

D1207D3


Positive control


(Fungal test)


Clotrimazole

1000 mg

>98%

J0506A


Fluconazole

1000 mg

>98.5%

J0118B


Voriconazole

100 mg

99.9%

A0420DS


Note: The remaining test samples and positive control substances will be returned to the test room on the day of the end of the test, and will be disposed of by the test room in a unified manner.


In vitro antimicrobial test


Test strains and their cultivation methods


Test strains


The types and quantities of test strains in vitro antimicrobial testing are shown in Table 2, and 48 strains of clinically isolated fine bacteria and clinically isolated yeast fungi were tested. All clinically isolated pathogens were collected clinically isolated and collected in China in the past three years. In the collection unit, it was identified by the VITEK-60 automatic microbial identification instrument, and then re-identified by the conventional method in the laboratory. The quality control strains were purchased from ATCC (American Type Culture Collection), China Center of Industrial Culture Collection, CICC®


Table 2 Inventory of test strains


Strain species


Strain name


Number of strains (strains)


Clinical isolation of bacteria


Staphylococcus aureus

12


Enterococcus faecalis

9


Enterococcus faecium

9


Streptococcus agalactiae

9


Escherichia coli

9


Clinical isolation of yeast fungi


Candida albicans

12


Candida glabrata

9


Candida kreuta

9


Candida tropicalis

9


Near-smooth Candida

9


Standard strains


(Bacteria)


Streptococcus pneumoniae ATCC 49619, Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 33591

4


Standard strains


(fungus)


Candida kreuthanis ATCC 6258, Candida paraglabraticum ATCC 22019, Candida albicans ATCC 10231, Candida albicans ATCC 90028

4


Culture medium and culture conditions


Bacterial medium: For resuscitation, MHA (Mueller-Hinton Agar) medium was used and incubated at 35 °C for 20-24 h. For MIC testing, CAMHB medium (Cation Adjusted Mueller-Hinton Broth) was used. Incubate at 35-37°C for 16-20 h.


Fungal medium: For strain recovery, yeast fungi were incubated at 35°C for 24h using SDA medium. For MIC testing, a liquid medium of fully synthetic medium RPMI-1640 (containing glutamine, without bicarbonate, with phenol red as a pH indicator) was used.


CAMHB Formula: Acid Hydrolyzed Casein (17.5g/L), Beef Powder (3.0 g/L) , soluble starch (1.5g/L), calcium ions (20-25 mg.) /L), magnesium ion (1 0-12.5 mg/L).


Preparation method of SDA and MHA medium: According to the instructions, take an appropriate amount of dry powder, add an appropriate amount of distilled water, and mix well. After boiling to completely dissolve, autoclave at 121°C for 15min. Mix well and pour into a sterile dish.


Preparation method of RPMI1640 liquid medium: take 10.4g of 1640 powder, add 900mL of distilled water to dissolve, and then addMOPS buffer (final concentration of 0.165mol/L, 34.53g), stir and mix well, and adjust with 1mol/L sodium hydroxideThe pH of the section was 7.0 (25°C), and then sterile ultrapure water was added to the volume to 1000 mL. Finally, sterilize with 0.22μm filter membrane (the filtered solution is divided into sterile triangular bottles) and stored at 4°C for later use.


In vitro antimicrobial test methods


The Clinical and Laboratory Standards Institute (CLSI) protocol for antimicrobial susceptibility testing was usedMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Eleventh Edition, M07- A11 ,2018】The recommended microbroth dilution method tests the minimum inhibitory concentration of antimicrobial peptide APIs and controls against bacteria ConcentrationMIC)。 [Reference Method for Broth DilutionAntifungal Susceptibility Testing of Yeasts; Approved StandardForth Edition, M27,4th Edition, 2017] Recommended microbroth dilution method for the determination of test and reference substancesThe minimum inhibitory concentration (MIC) for fungi was analyzed using the susceptibility resistance criteria recommended by CLSI (see Table 4).Resistance of the positive control drug to the strain.


(1) Preparation of test samples


Weigh an appropriate amount of the test sample powder, and use sterile pure water or DMSO to prepare the mother liquor with a concentration of 5120 mg/L (test sample and antimicrobial polypeptide positive control) or, according to the solubility1280 mg/L (the rest of the positive controls). Ten-fold dilution to 512 mg/L or 2 with sterile broth (CAMHB medium for bacteria and RPMI1640 medium for fungi) respectively 128 mg/L, half of the volume of the solution was divided into a 96-well filling tank, and the other half volume of the solution was diluted twice with the corresponding sterile broth and added to 96Inside the well loading tank. Repeat the above steps so that the concentrations of the test sample and the positive control of antimicrobial polypeptide in the 1st to 1st well in the loading tank are 512 and 256 respectively128643216842, 1, 0.5mg/L, and the concentrations of the remaining positive controls were 128, 64, and 32, respectively1684210.50.250.125 mg/LReady-to-use.


(2) Preparation of inoculum


Preparation of bacterial sylvestres: MH agar (Mueller-Hinton Agar) cultured from 18-24 hSelect a few colonies in a flat dish and make a bacterial suspension directly in sterile normal saline, and adjust the concentration of the bacterial suspension to 0.5 McS. The corrected bacterial solution was diluted to (4~8105 CFU/mL with broth, and it was prepared for immediate use.


Preparation of fungal solution: After inoculating the test bacteria into Shasser's glucose agar medium (SDA) and incubating at 35°C for 24 h, select a few colonies from the plate and prepare the bacterial suspension directly in sterile normal saline. Adjust the concentration of the bacterial suspension to 0.5 McClavins (equivalent to (1-5106CFU/ml). The calibrated bacterial solution was diluted 100-fold with normal saline, and then diluted 10-fold with sterile RPMI1640 liquid medium to (1~5103 CFU/mL, ready to use.


(3) Sampling and inoculation


Pipette 100μL of the above different concentrations of the test sample solution into the 1st to 11th wells of a sterile 96-well polystyrene plate, and take another 100 of the above inoculum μL was added to holes 1 through 11. The concentrations of the test sample and the positive control of antimicrobial polypeptide in the well were 256, 128, 64 and 32, respectively、1684210.50.25 mg/L, and the concentrations of the remaining positive controls were 16, 8, 4, 2, and 1 in turn0.50.250.1250.060.030.015 mg/L。 The concentration of the final bacteria is (2~4105CFU/mL, and the concentration of yeast fungi is0.5~2.5)×103 CFU/mLWells 1 and 2 were set up as growth control wells, and the wells contained 100 μL of inoculum and 100 μL Sterile broth. The test substance and inoculum in each well are mixed and sealed.


(4) Incubation


Bacterial incubation: The inoculated 96-well plate was incubated in a 37°C incubator for 16-20 h.


Fungal incubation: Place the inoculated 96-well plate at 35 °C for 24-48 h.


(5) Interpretation of MIC endpoints


Bacterial key interpretation: Endpoint interpretation: After the end of culture, the growth of bacteria in each well was observed. All drugs are given the lowest inhibitory concentration (MIC) at the lowest drug concentration that completely inhibits bacterial growth within the pore.


Interpretation of fungal endpoints: After the end of culture, the growth of bacteria in each well was observed. iCAMP016, BF-30, iCAMP018 and PL-18 were the lowest inhibitory concentrations (MICs) at the lowest drug concentration that completely inhibited the growth of bacteria in the wells。 Clotrimazole, fluconazole, and voriconazole are the lowest inhibitory concentrations (MIC) at the lowest drug concentration that inhibits the growth of 50% of bacteria in the wells.


Table 3 Sample Preparation Information


The name of the sample


Solvent (mother liquor preparation)


Concentration of mother liquor (mg/L).


MIC test final concentration range (mg/L).

iCAMP016


Sterile pure water

5120

0.25-256

BF-30

iCAMP018

PL-18


Clindamycin


Sterile pure water

1280

0.015-16


Levofloxacin


Cefuroxime sodium


Moxifloxacin hydrochloride


Clotrimazole

DMSO

1280

0.015-16


Fluconazole


Voriconazole


Table 4 Criteria for judging susceptibility and resistance of positive controls such as clindamycin


The name of the drug


MIC interpretation criteria (mg/L).


remark


Judging criteria


Reference Sources:

S

SDD

I

R


Clindamycin

≤0.5

-

1-2

4


Staphylococcus spp

CLSI

≤0.25

-

0.5

≥1


β-hemolytic streptococcus

CLSI


Levofloxacin

≤1

-

2

4


Staphylococcus spp

CLSI

≤2

-

4

8


Enterococci, β-hemolytic streptococcus

CLSI


Moxifloxacin

≤0.5

-

1

2


Staphylococcus spp

CLSI


Fluconazole

≤2

-

-

≥8


Candida albicans, Candida paranguinus, Candida tropicalis

CLSI

-

-

-

≥64


Candida glabrata

CLSI


Voriconazole

≤0.12

-

0.25-0.5

≥1


Candida albicans, Candida paranguinus, Candida tropicalis

CLSI

≤0.5

-

1

≥2


Candida kreuta

CLSI


Remarks: S, susceptible; I, intermediate; R, resistant; SDD,Susceptible-dose Dependent


quality control


For bacterial MIC testing, clindamycin was used as the quality control compound and Staphylococcus aureus ATCC 29213 was used as the quality control strain. For the MIC reference values and susceptibility resistance judgment standards of quality control antibiotics to quality control strains, please refer to CLSI 2024 (Performance standards for Antimicrobial Susceptibility Testing: 34th Information Supplement. M100) The MIC reference value of clindamycin against Staphylococcus aureus ATCC 29213 was 0.06-0.25 mg/L.


For fungal MIC testing, voriconazole was used as the quality control compound and Candida kritul ATCC 6258 was used as the quality control strain. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved StandardForth Edition, M27,4th Edition ,2017】。 The reference MIC value of voriconazole against Candida kritis ATCC 6258 ranged from 0.06 to 0.5 mg/L.


The MIC value of Clindamycin against Staphylococcus aureus ATCC 29213 was 0.125 mg/L for Clindamycin and 0.125 mg/L for Clindamycin ATCC 6258The MC value is 025 mg/L, all within the quality control range specified by CL SI, indicating that the test system is stable and the data is reliable.


Reagents & Instruments


Main reagents and culture media


Table 5 Information on the main test agents and culture media


name


lot number


expiration date


Manufacturer

CAMHB

1242967

2025.07.31


BD Inc. in the United States

MHA

3207590

2025.12.14

OXOID

Sabouraud Dextrose Agar

3543794

2027.09

OXOID

RPMI1640 Medium

SLCL5374

2024.07.25

SIGMA-ALDRICH CHEMIE GmbH, Riedstr


Mannitol sodium chloride agar medium

20231222


3 years


Qingdao Hi-Tech Park Haibo Biotechnology Co., Ltd


Saline

L222062008

2025.05


Sichuan Kelun Pharmaceutical Co., Ltd


Chloramphenicol additives

3704823

2025.08

OXOID


MOPS buffer dry powder

2024/01

2025.12

Beijing Biotopped Science&technolog Co. Ltd

DMSO

2023010401

2026.10


Chengdu Kelong Chemical Co., Ltd


Main instruments


Table 6 Main instrument information


name


Model


Manufacturer


Pipettes

30-300 μL/ 100-1000 μL

Eppendorf


Microplate reader

Multiskan FC

THERMO FISHER


Biological safety cabinets

HR40-IIA2


Qingdao Haier Special Electric Appliance Co., Ltd


Electrically heated incubator

DHP-9272


Shanghai Yiheng Scientific Instrument Co., Ltd


Autoclave

YXQ-LS-100G


Shanghai Boxun Instrument Equipment Co., Ltd


Electric blast drying oven

1011s


Tianjin Hongnuo Instrument Co., Ltd


Test results


Analysis of antimicrobial activity of antimicrobial peptide iCAMP016 and control drug on 48 strains of clinically isolated bacteria in vitro


The in vitro MIC values of the antimicrobial polypeptide iCAMP016 and the control drug against 48 strains of clinically isolated bacteria are shown in Table 7 and Table 8.


(1) Staphylococcus aureus


The MIC values of the antimicrobial peptide iCAMP016 against the 12 strains of Staphylococcus aureus tested ranged from 8 to 32 mg/L. Its antibacterial activity is comparable to iCAMP018 and PL-18, stronger than clindamycin and BF-30, and weaker than the control drug levofloxacin, moxifloxacin hydrochloride and cefuroxime sodium.


Clindamycin was effective against 12 strains of Staphylococcus aureus tested (including 6 strains of methicillin-resistant Staphylococcus aureus, 5 strains of methicillin-susceptible Staphylococcus aureus, and linezolid-resistant Staphylococcus aureus). 1 strain) with a MIC value range of 0.06->16 mg/L, and the resistance rate75.0%; The MIC value of cefuroxime sodium ranged from 1->16 mg/L; Most of the MIC values of levofloxacin and moxifloxacin hydrochloride are 0.03-1 mg/L, and the resistance rate is high Both were 8.3%. The MIC values of BF-30 were all >256 mg/L, and there was no obvious antibacterial activity.


(2) Enterococcus faecalis


The MIC value of the antimicrobial polypeptide iCAMP016 against the 9 strains of Enterococcus faecalis tested was 16-32 mg/L. Its antibacterial activity is stronger than iCAMP018, PL-18 and BF-30, and comparable to that of the control drugs clindamycin and cefuroxime sodium. Weaker than the control drugs levofloxacin and moxifloxacin hydrochloride.


The MIC values of the control product iCAMP018 against the 9 strains of Enterococcus faecalis were 32-64 mg/L. The MIC values of BF-30 and PL-18 ranged from 64->256 mg/L. The MIC values of clindamycin and cefuroxime sodium ranged from 16->16 mg/L; The MIC value of levofloxacin ranged from 0.5->16 mg/L, and the drug resistance rate was 33.3%. The MIC values of moxifloxacin hydrochloride ranged from 0.125->16 mg/L.


(3) Enterococcus faecium


The MIC value of the antimicrobial polypeptide iCAMP016 against the 9 strains of Enterococcus faecium tested was 2 mg/L. Its antibacterial activity is stronger than that of the control products iCAMP018, PL-18 and BF-30, and stronger than levofloxacin and moxifloxacin hydrochloride, clindamycin and cefuroximeSodium.


The MIC values of the control products iCAMP018 and PL-18 against the 9 strains of Enterococcus faecium tested ranged from 2-8 mg/L. faecesBF-30 has MIC values ranging from 8 to 32 mg/L. The MIC values of clindamycin, levofloxacin, cefuroxime sodium, and moxifloxacin hydrochloride were mostly 16->16 mg/L, The drug resistance rate of levofloxacin was 100.0%.


(4) Streptococcus agalactiae


The MIC value of the antimicrobial polypeptide iCAMP016 against the 9 strains of Streptococcus agalactiae tested was 2-8 mg/L. Its antibacterial activity is stronger than that of the control products iCAMP018, PL-18 and BF-30, and weaker than that of the control drugs levofloxacin and moxifloxacin hydrochlorideClindamycin and cefuroxime sodium.


The MIC values of the control products iCAMP018 and PL-18 against the 9 strains of Streptococcus agalactiae ranged from 8 to 64 mg/L. lactiae, the MIC value of BF-30 ranged from 128->256 mg/L. The MIC values of cefuroxime sodium and moxifloxacin hydrochloride ranged from 0.03 to 4 mg/L; The MIC value of levofloxacin ranged from 0.5->16 mg/L, and its resistance rate was 22.2%.; The MIC value of clindamycin ranged from 0.06->16 mg/L, and its resistance rate was 55.5%.


(5) Escherichia coli


The MIC value of the antimicrobial polypeptide iCAMP016 against the 9 strains of Escherichia coli was 2-8 mg/LIts antibacterial activity is comparable to that of the control drugs BF-30, iCAMP018 and PL-18, stronger than the control drugs clindamycin and cefuroxime sodium, and comparable to the control drugs levofloxacin and moxifloxacin hydrochlorideor weaker.


The MIC values of clindamycin against 9 strains of Escherichia coli were >16 mg/L. The MIC values of moxifloxacin hydrochloride ranged from 0.03->16 mg/L; The MIC value of levofloxacin was 0.03->16 mg/L, and its drug resistance rate was 66.7%. The MIC value of cefuroxime sodium ranged from 4->16 mg/L, and its resistance rate was 55.6%.


Page 20 of 45

总结报告 专题代号:2415AS1


TABLE 7 Minimum inhibitory concentration and resistance rate of antimicrobial polypeptide iCAMP016 and control drugs against 48 strains of clinically isolated bacteria in vitro-MIC50 MIC90MICrangemg/L


bacteria


(Number of plants)


Antimicrobials


Judging criteria

MICmg/L


Resistance rate (%).


Intermediary resistance rate (%).


Sensitivity rate (%).


Sensitive(s).


Intermediary (I).


Antimicrobial resistance (R).

MIC50

MIC90

MICrange


mode


Staphylococcus aureus (12).

iCAMP016

-

-

-

8

8

8-32

8

-

-

-

BF-30

-

-

-

>256

>256

>256

>256

-

-

-

iCAMP018

-

-

-

8

16

8-32

8

-

-

-

PL-18

-

-

-

16

16

8-32

16

-

-

-


Clindamycin

≤0.5

1-2

≥4

>16

>16

0.06->16

>16

75.0

0.0

25.0


Levofloxacin

≤1

2

≥4

0.25

1

0.125->16

0.25

8.3

0.0

91.7


Cefuroxime sodium

-

-

-

2

>16

1->16

2

-

-

-


Moxifloxacin hydrochloride

≤0.5

1

≥2

0.06

0.25

0.03-8

0.06

8.3

0.0

91.7


Enterococcus faecalis (9).

iCAMP016

-

-

-

32

32

16-32

32

-

-

-

BF-30

-

-

-

>256

>256

128->256

>256

-

-

-

iCAMP018

-

-

-

32

64

32-64

32

-

-

-

PL-18

-

-

-

>256

>256

64->256

>256

-

-

-


Clindamycin

-

-

-

>16

>16

16->16

>16

-

-

-


Levofloxacin

≤2

4

≥8

1

>16

0.5->16

1

33.3

0.0

66.7


Cefuroxime sodium

-

-

-

>16

>16

>16

>16

-

-

-


Moxifloxacin hydrochloride

-

-

-

0.25

>16

0.125->16

0.25

-

-

-


Continued from Table 7


bacteria


(Number of plants)


Antimicrobials


Judging criteria

MICmg/L


Resistance rate (%).


Intermediary resistance rate (%).


Sensitivity rate (%).


Sensitive(s).


Intermediary (I).


Antimicrobial resistance (R).

MIC50

MIC90

MICrange


mode


Enterococcus faecium (9).

iCAMP016

-

-

-

2

2

2

2

-

-

-

BF-30

-

-

-

32

32

8-32

32

-

-

-

iCAMP018

-

-

-

4

4

2-4

4

-

-

-

PL-18

-

-

-

4

8

4-8

4

-

-

-


Clindamycin

-

-

-

>16

>16

0.06->16

>16

-

-

-


Levofloxacin

≤2

4

≥8

>16

>16

>16

>16

100.0

0.0

0.0


Cefuroxime sodium

-

-

-

>16

>16

>16

>16

-

-

-


Moxifloxacin hydrochloride

-

-

-

>16

>16

2->16

>16

-

-

-


Streptococcus agalactiae (9).

iCAMP016

-

-

-

2

8

2-8

2

-

-

-

BF-30

-

-

-

256

>256

128->256

>256

-

-

-

iCAMP018

-

-

-

8

16

8-16

8

-

-

-

PL-18

-

-

-

16

64

8-64

16

-

-

-


Clindamycin

≤0.25

0.5

≥1

1

32

0.06->16

>16

44.4

11.1

44.4


Levofloxacin

≤2

4

≥8

1

>16

0.5->16

0.5

22.2

0.0

77.8


Cefuroxime sodium

-

-

-

0.03

0.06

0.03-0.06

0.03

-

-

-


Moxifloxacin hydrochloride

-

-

-

0.25

4

0.06-4

0.125,0.25

-

-

-


Continued from Table 7


bacteria


(Number of plants)


Antimicrobials


Judging criteria

MICmg/L


Resistance rate (%).


Intermediary resistance rate (%).


Sensitivity rate (%).


Sensitive(s).


Intermediary (I).


Antimicrobial resistance (R).

MIC50

MIC90

MICrange


mode


Escherichia coli (9).

iCAMP016

-

-

-

2

8

2-8

2

-

-

-

BF-30

-

-

-

2

4

2-4

2

-

-

-

iCAMP018

-

-

-

8

16

4-16

4,8

-

-

-

PL-18

-

-

-

8

16

4-16

8

-

-

-


Clindamycin

-

-

-

>16

>16

>16

>16

-

-

-


Levofloxacin

≤0.5

1

≥2

4

>16

0.03->16

0.5,8

55.6

11.1

33.3


Cefuroxime sodium

≤8

16

≥32

>16

>16

4->16

>16

55.6

0.0

44.4


Moxifloxacin hydrochloride

-

-

-

4

>16

0.03->16

0.5,16,>16

-

-

-


Table 8-1 MIC distribution and cumulative inhibition rate of 12 strains of Staphylococcus aureus by antimicrobial peptide iCAMP016 and control drug (%)


Antimicrobials

 

MICmg/L

 

>256

256

128

64

32

>16

16

8

4

2

1

0.5

0.25

0.125

0.06

0.03

iCAMP016


Number of strains

 

 

 

 

1

 

1

10

 

 

 

 

 

 

 

 


Cumulative

 

 

 

 

12

 

11

10

 

 

 

 

 

 

 

 


Accumulation rate (%)

 

 

 

 

100.0

 

91.7

83.3

 

 

 

 

 

 

 

 

BF-30


Number of strains

12

 


Cumulative

12

 


Accumulation rate (%)

100.0

 

iCAMP018


Number of strains

 

 

 

 

1

 

3

8

 

 

 

 

 

 

 

 


Cumulative

 

 

 

 

12

 

11

8

 

 

 

 

 

 

 

 


Accumulation rate (%)

 

 

 

 

100.0

 

91.7

66.7

 

 

 

 

 

 

 

 

PL-18


Number of strains

 

 

 

 

1

 

6

5

 

 

 

 

 

 

 

 


Cumulative

 

 

 

 

12

 

11

5

 

 

 

 

 

 

 

 


Accumulation rate (%)

 

 

 

 

100.0

 

91.7

41.7

 

 

 

 

 

 

 

 


Clindamycin


Number of strains

 

 

 

 

 

9

 

 

 

 

 

 

 

1

2

 


Cumulative

 

 

 

 

 

12

 

 

 

 

 

 

 

3

2

 


Accumulation rate (%)

 

 

 

 

 

100.0

 

 

 

 

 

 

 

25.0

16.7

 


Levofloxacin


Number of strains

 

 

 

 

 

1

 

 

 

 

1

2

5

3

 

 


Cumulative

 

 

 

 

 

12

 

 

 

 

11

10

8

3

 

 


Accumulation rate (%)

 

 

 

 

 

100.0

 

 

 

 

91.7

83.3

66.7

25.0

 

 


Cefuroxime sodium


Number of strains

 

 

 

 

 

4

 

 

 

7

1

 

 

 

 

 


Cumulative

 

 

 

 

 

12

 

 

 

8

1

 

 

 

 

 


Accumulation rate (%)

 

 

 

 

 

100.0

 

 

 

66.7

8.3

 

 

 

 

 


Moxifloxacin hydrochloride


Number of strains

 

 

 

 

 

 

 

1

 

 

 

 

1

1

8

1


Cumulative

 

 

 

 

 

 

 

12

 

 

 

 

11

10

9

1


Accumulation rate (%)

 

 

 

 

 

 

 

100.0

 

 

 

 

91.7

83.3

75.0

8.3


Table 8-2 MIC distribution and cumulative inhibition rate (%) of the antimicrobial polypeptide iCAMP016 and the control drug against 9 strains of Enterococcus faecalis


Antimicrobials

 

MICmg/L

 

>256

256

128

64

32

>16

16

8

4

2

1

0.5

0.25

0.125

0.06

0.03

iCAMP016


Number of strains

5

4


Cumulative

9

4


Accumulation rate (%)

100.0

44.4

BF-30


Number of strains

8

1


Cumulative

9

1


Accumulation rate (%)

100.0

11.1

iCAMP018


Number of strains

1

8


Cumulative

9

8


Accumulation rate (%)

100.0

88.9

PL-18


Number of strains

6

1

2


Cumulative

9

3

2


Accumulation rate (%)

100.0

33.3

22.2


Clindamycin


Number of strains

5

4


Cumulative

9

4


Accumulation rate (%)

100.0

44.4


Levofloxacin


Number of strains

3

1

4

1


Cumulative

9

6

5

1


Accumulation rate (%)

100.0

66.7

55.6

11.1


Cefuroxime sodium


Number of strains

9


Cumulative

9


Accumulation rate (%)

100.0


Moxifloxacin hydrochloride


Number of strains

1

1

1

5

1


Cumulative

9

8

7

6

1


Accumulation rate (%)

100.0

88.9

77.8

66.7

11.1


Table 8-3 MIC distribution and cumulative inhibition rate (%) of antimicrobial polypeptide iCAMP016 and control drug against 9 strains of Enterococcus faecali


Antimicrobials

 

MICmg/L

 

>256

256

128

64

32

>16

16

8

4

2

1

0.5

0.25

0.125

0.06

0.03

iCAMP016


Number of strains

9


Cumulative

9


Accumulation rate (%)

100.0

BF-30


Number of strains

6

2

1


Cumulative

9

3

1


Accumulation rate (%)

100.0

33.3

11.1

iCAMP018


Number of strains

7

2


Cumulative

9

2


Accumulation rate (%)

100.0

22.2

PL-18


Number of strains

3

6


Cumulative

9

6


Accumulation rate (%)

100.0

66.7


Clindamycin


Number of strains

8

1


Cumulative

9

1


Accumulation rate (%)

100.0

11.1


Levofloxacin


Number of strains

9


Cumulative

9


Accumulation rate (%)

100.0


Cefuroxime sodium


Number of strains

9


Cumulative

9


Accumulation rate (%)

100.0


Moxifloxacin hydrochloride


Number of strains

6

2

1


Cumulative

9

3

1


Accumulation rate (%)

100.0

33.3

11.1


Table 8-4 MIC distribution and cumulative inhibition rate (%) of the antimicrobial polypeptide iCAMP016 and the control drug against 9 strains of Streptococcus agalactiae


Antimicrobials

 

MICmg/L

 

>256

256

128

64

32

>16

16

8

4

2

1

0.5

0.25

0.125

0.06

0.03

iCAMP016


Number of strains

1

3

5


Cumulative

9

8

5


Accumulation rate (%)

100.0

88.9

55.6

BF-30


Number of strains

4

3

2


Cumulative

9

5

2


Accumulation rate (%)

100.0

55.6

22.2

iCAMP018


Number of strains

1

8


Cumulative

9

8


Accumulation rate (%)

100.0

88.9

PL-18


Number of strains

1

1

4

3


Cumulative

9

8

7

3


Accumulation rate (%)

100.0

88.9

77.8

33.3


Clindamycin


Number of strains

4

1

1

3


Cumulative

9

5

4

3


Accumulation rate (%)

100.0

55.6

44.4

33.3


Levofloxacin


Number of strains